Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

Inclusion Criteria: * Male or non-pregnant and non-lactating female, and ≥ 18 years of age. * Diagnosis of angina pectoris or unstable angina pectoris or patients with documented silent ischemia. * Left ventricular ejection fraction ≥30% * Patient has undergone successful and uncomplicated stenting of up to 2 de novo lesions in native coronary arteries OR patient has undergone successful and uncomplicated balloon angioplasty of up to 2 in-stent restenosis (ISR) lesions in native coronary arteries, but not both. * Thrombolysis In Myocardial Infarction (TIMI) 3 coronary flow post-stenting for de novo lesions or post balloon angioplasty for ISR lesions. * No angiographic evidence of thrombus post-procedure. * Target vessel ≥2.5 mm diameter (by angiography). * Each de novo lesion is such that it is stented with ≤ 25 mm of single continuous stent. * Each in-stent restenosis (ISR) lesion is ≤ 25 mm in length. * There is at least 5 mm of non-diseased vessel on either side of target lesion(s). * By intravascular ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 2.5 mm or an in-stent luminal area ≥ 5.0 mm\^2 * Patient or guardian has provided a signed written informed consent to participate in the study and in all follow-up assessments using a form that is approved by the local Institutional Review Board (IRB)/Ethics Committee of the investigative site. Exclusion Criteria: * Target de novo lesion was treated with a drug-eluting stent * Target ISR lesion requir…